Steven Perrin - 21 Nov 2024 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Role: President, Director
Signature: /s/ Paul Little, as attorney-in-fact for Steve Perrin
Issuer symbol: ELDN
Transactions as of: 21 Nov 2024
Net transactions value: $0
Form type: 4
Filing time: 22 Nov 2024, 17:00:06 UTC
Previous filing: 14 Jun 2024
Next filing: 13 Jan 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELDN	Stock Option (right to buy)	Award	$0	+840,438		$0.000000	840,438	21 Nov 2024	Common Stock	840,438	$2.30	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 840,438 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 315,164 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 525,274 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027.

Content

This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 840,438 shares of underlying Common Stock on November 21, 2024 and time-based vesting criteria with respect to 315,164 shares of underlying Common Stock on November 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 525,274 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027.